InfuSystem Holdings stock kpis
Want to see INFU full AI Analyst Report?
Revenue by Segment
In Q3 2026, InfuSystem Holdings reported revenue by segment of $25.81M (Patient Services) and $13.37M (Device Solutions).
Breaks down sales across the company’s different business units, showing where growth is coming from and how concentrated the revenue base is. For InfuSystem, a shift toward recurring service and rental revenue improves predictability, while dependence on a few products or customers raises exposure to reimbursement and procurement cycles.
Patient Services is the steady growth engine—buoyed by Oncology and rapidly scaling Wound Care—while Device Solutions shows pronounced volatility driven by equipment‑sale swings and the GE contract restructuring. That restructuring is a near‑term revenue headwind but margin‑accretive, helping consolidated gross margins and adjusted EBITDA. The company’s ability to hit its pro‑forma growth and mid‑20s EBITDA target depends on stabilizing Device Solutions equipment sales and restoring Patient Services margins (currently pressured by mix, maintenance costs and ERP transition); those are the key catalysts and risks to watch.
INFU Revenue by Segment
| Period | Patient Services | Device Solutions |
|---|---|---|
| Q3 2026Sep 30, 2026 | $25.81M | $13.37M |
| Q2 2026Jun 30, 2026 | $24.79M | $13.96M |
| Q1 2026Mar 31, 2026 | $22.11M | $11.58M |
| Q4 2025Dec 31, 2025 | $21.88M | $15.95M |
| Q3 2025Sep 30, 2025 | $22.36M | $16.07M |
| Q2 2025Jun 30, 2025 | $21.52M | $16.25M |
| Q1 2025Mar 31, 2025 | $20.77M | $15.82M |
| Q4 2024Dec 31, 2024 | $20.76M | $14.89M |
| Q3 2024Sep 30, 2024 | $20.78M | $16.53M |
| Q2 2024Jun 30, 2024 | $20.25M | $15.19M |
| Q1 2024Mar 31, 2024 | $18.59M | $15.12M |
| Q4 2023Dec 31, 2023 | $19.16M | $14.28M |
| Q3 2023Sep 30, 2023 | $19.29M | $14.22M |
| Q2 2023Jun 30, 2023 | $19.32M | $14.10M |
| Q1 2023Mar 31, 2023 | $18.77M | $13.23M |
| Q4 2022Dec 31, 2022 | $17.62M | $12.82M |
| Q3 2022Sep 30, 2022 | $17.38M | $11.51M |
| Q2 2022Jun 30, 2022 | $17.24M | $11.56M |
| Q1 2022Mar 31, 2022 | $16.64M | $11.61M |
| Q4 2021Dec 31, 2021 | $16.77M | $11.02M |
| Q3 2021Sep 30, 2021 | $16.58M | $11.43M |
| Q2 2021Jun 30, 2021 | $16.33M | $10.10M |
| Q1 2021Mar 31, 2021 | $15.91M | $10.00M |
| Q4 2020Dec 31, 2020 | $15.70M | $10.42M |
| Q3 2020Sep 30, 2020 | $15.64M | $10.95M |
| Q2 2020Jun 30, 2020 | $15.61M | $11.65M |
| Q1 2020Mar 31, 2020 | $14.13M | $8.66M |

